About Shanghai Obio Technology Company

Founded in 2013, the company upholds the mission of "integrating resources to serve the life sciences" and adheres to the core values of "customer first, efficient execution, pursuit of excellence, innovative breakthroughs, and integrity combined with pragmatism." It comprehensively facilitates the translation of cell and gene therapies from research into clinical applications, and has grown into a high-tech enterprise that integrates three major business pillars: foundational research services for gene function; commercial-scale manufacturing services for clinical-grade cell and gene therapy products; and regenerative medicine services. For many years, the company has focused on and deeply cultivated the field of cell and gene therapy technical services, providing CRO services such as the development of gene therapy vectors, gene function studies, and drug target and efficacy research to support basic research in cell and gene therapy; offering CDMO services including process development and testing, IND–CMC pharmaceutical studies, and GMP-compliant production of clinical samples and commercial products to support the R&D of cell and gene therapy drugs; and delivering technical services in regenerative medicine and anti-aging fields, such as cell preparation, production of cell-derived products like recombinant proteins and exosomes, and cell storage, along with the manufacturing and sales of biological raw materials, biologics, reagents, and other related products. Key offerings include gene therapy vector development services, gene function research services, genetic testing services, pre-IND new drug services, post-IND new drug services, regenerative medicine preparation services, cell storage and ancillary services, biological raw materials, biologic products, reagents, test kits, and other products.